Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

from the Department of Defense to advance a next generation mammalian cell culture expression system for our recombinant chemical nerve agent bioscavenger program."

Conference Call and Webcast InformationPharmAthene management will be hosting a conference call to discuss the Company's third quarter 2011 financial and operating results.  The call is scheduled to begin at 8:30 a.m. Eastern Time on Wednesday, November 9, 2011 and is expected to last approximately 30 minutes. The dial-in number within the United States is 888-268-4176.  The dial-in number for international callers is 617-597-5493.  The participant passcode is 54772588.

A replay of the conference call will be available beginning at approximately 11:30 a.m. Eastern Time on November 9, 2011 until approximately 11:30 a.m. Eastern Time on December 9, 2011.  The dial-in number to access the replay from within the United States is 888-286-8010.   For international callers, the dial-in number is 617-801-6888.  The participant passcode is 88200860.

The conference call will also be webcast and can be accessed from the Company's website at www.PharmAthene.com.  A link to the webcast may be found under the Investor Relations section of the website.  

About PharmAthene, Inc.PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Recombinant BChE- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

  • In addition, pu
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    7. PharmAthene Completes $6.5 Million Registered Direct Offering
    8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
    11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be ... cell credentialing course to local area veterinarians. , The tour and course will be ... at no charge) at VetStem’s Poway facility. Staff members are welcome to attend with ...
    (Date:7/28/2015)... , July 28, 2015  Kerastem Technologies announce ... from the U.S. FDA Center For Biologics Evaluation and ... to conduct a clinical trial investigating the safety and ... female and early male pattern baldness (androgenic alopecia). ... trial, follows initial clinical work in Europe ...
    (Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
    (Date:7/28/2015)... , July 28, 2015 ... company utilizing its proprietary plant-based rhCollagen technology for ... has been appointed Senior Director of Business Development, ... http://photos.prnewswire.com/prnh/20150728/246955 ) , Ms. ... marketing, regulatory and business strategy. Prior to joining ...
    Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
    ... ... trainer Dr. Rebecca Fitzgerald, known among her medical colleagues as the "Sculptra guru" here in ... physicians at this year,s 4 day SDEF Cosmetic Dermatology Seminar held in Santa Monica, Ca. ... Los Angeles, Ca ...
    ... , SANTA ANA, Calif. , ... partnership with Prodimed, a company specializing in women,s health, located ... be distributing Prodimed,s extensive line of embryo transfer catheters, oocyte ... , , Prodimed has a ...
    ... PALO ALTO, Calif., July 21, Varian, Inc. (NasdaqGS: VARI) plans to ... 2009 after 1:00 p.m. Pacific Time (PT) on Wednesday, July 29, 2009. ... review those quarterly results is scheduled to follow at 2:00 p.m. PT ... webcast can be accessed from Varian, Inc.,s Web site at ...
    Cached Biology Technology:Looking Older Than You Are May Have Little to Do With Wrinkles 2Looking Older Than You Are May Have Little to Do With Wrinkles 3
    (Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
    (Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
    (Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
    Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
    ... A new assessment of the Arctic,s biodiversity reports a 26 ... Populations of lemmings, caribou and red knot are some ... 34 years, according to the first report from The Arctic ... the Arctic,s ecosystems and wildlife are responding to environmental change. ...
    ... by Wayne L. Backes, PhD, Professor of Pharmacology and Associate ... School of Medicine, has found that drug metabolism depends not ... also how they interact, and that can be the difference ... or is converted into a toxic or carcinogenic byproduct. The ...
    ... Angeles, Calif., March 16, 2010Researchers at the Keck School ... have identified a key cellular mechanism that guides embryonic ... to a number of common congenital heart defects. ... the First Heart Field, which includes the left ventricle ...
    Cached Biology News:High Arctic species on thin ice 2LSUHSC research increases understanding of drug metabolism 2USC researchers identify key mechanism that guides cells to form heart tissue 2
    This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
    Phospho-FAK (Tyr576/577) Antibody...
    Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
    Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
    Biology Products: